Q-omics provides the consensus-scored CACNA1D profile across patient tissues and cancer cell-line models. CACNA1D expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CACNA1D is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, CACNA1D RNA expression shows 20,038 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight BRCA, and THCA as cancer lineages where CACNA1D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CACNA1D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CACNA1D survival associations across molecular data types. CACNA1D RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CACNA1D RNA expression–survival associations across cancer types. High CACNA1D expression shows favorable associations in BRCA, COAD, KIRP, KIRC, HNSC and CESC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CACNA1D RNA expression.
This table summarizes CACNA1D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CACNA1D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CACNA1D shows lower tumor expression in THCA, HNSC, LUAD and LUSC and higher tumor expression in COAD and LIHC. The THCA box plot shows higher CACNA1D RNA expression in normal versus tumor tissue (log2 FC = −1.232, t-test p < 0.001).
This table shows molecular features associated with CACNA1D in patient tissues and cancer cell lines. In patient samples, CACNA1D shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CACNA1D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BREAST.
